Fibroblast activation protein (FAP) as a prognostic biomarker and radiomics-based predictor of angiogenesis-associated recurrence in Adamantinomatous craniopharyngioma
Performance · RecurrenceResult — go to the resultHR for recurrence 9.890Authors' conclusion
FAP is a prognostic biomarker in ACP, with high expression indicative of increased recurrence risk. The radiomics model offers a non-invasive approach for preoperative risk stratification, potentially guiding surgical decision-making and anti-angiogenic therapeutic strategies.
Study context
- Population
- Adamantinomatous craniopharyngioma (ACP) cases; transcriptomic data from 110 ACP cases across two external databasesIHC cohort
- Participants
- 54 participants
- Comparison
- High vs low FAP expression
- Outcome
- Recurrence
Methodological detailsimmunohistochemistry, transcriptomic analysis of external databases, immunofluorescence, MRI radiomics, internal and external validation
- Immunohistochemistry
- Transcriptomic analysis of external databases
- Immunofluorescence
- MRI radiomics
- Internal and external validation
Performance
As reported in the abstract
HR for recurrence
9.890
P = 0.0340
- Shorter PFS in high-FAP tumors
- P = 0.03
Further findings
Radiomics model (T1/T2-weighted MRI) predicting FAP expression
- AUC, training set
- 0.742
- AUC, internal validation set
- 0.822
- AUC, external validation set
- 0.686
Pathways and co-localization
- High FAP associated with extracellular matrix remodeling, angiogenesis and inflammatory pathway activation
- FAP+ cancer-associated fibroblasts (CAFs) co-localized with angiogenic markers
Original publication
FAP as a prognostic biomarker and radiomics-based predictor of angiogenesis-associated recurrence in Adamantinomatous craniopharyngioma. Pituitary. Published 1 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →